Table 3.
Endocrine therapy Kaplan-Meier early discontinuation rates and hazard ratios from a joint model.
| Ratio | 95% CI | p-value | |
|---|---|---|---|
| Arm Assignment with receipt of Chemo | |||
| Arm C (RS 11-25) or D (RS 26-100) , Received Chemo | Ref | ||
| Arm C (RS 11-25) or D (RS 26-100), No Chemotherapy | 1.71 | (1.37, 2.14) | 0.000003 |
| Arm A (RS 0-10) or B (RS 11-25) , Received Chemotherapy | 1.03 | (0.66, 1.61) | 0.89 |
| Arm A (RS 0-10) or B (RS 11-25), No Chemotherapy received | 1.18 | (1.01, 1.38) | 0.03 |
| Age | |||
| 40 years or younger | Ref | ||
| 41 to 50 years old | 0.70 | (0.54, 0.89) | 0.005 |
| 51 to 60 years old | 0.52 | (0.39, 0.70) | 0.00001 |
| 61 to 70 | 0.46 | (0.34, 0.64) | 0.000003 |
| 71 and older | 0.57 | (0.38, 0.86) | 0.008 |
| Race | |||
| White | Ref | ||
| Black | 0.73 | (0.57, 0.93) | 0.01 |
| Asian | 0.50 | (0.34, 0.75) | 0.0007 |
| Other or unknown | 1.07 | (0.79, 1.45) | 0.65 |
| Ethnicity | |||
| Non-Hispanic | Ref | ||
| Hispanic | 0.87 | (0.70, 1.09) | 0.23 |
| Ethnicity not reported | 0.82 | (0.66, 1.02) | 0.07 |
| Insurance Type (US participants only) | |||
| Private | Ref | ||
| Medicare | 1.10 | (0.88, 1.37) | 0.41 |
| Medicaid | 1.53 | (1.23, 1.92) | 0.0002 |
| Military/VA | 0.80 | (0.38, 1.69) | 0.56 |
| None | 1.65 | (1.25, 2.17) | 0.0003 |
| Other or unknown | 0.84 | (0.40, 1.78) | 0.65 |
| Neighborhood Deprivation Index (NDI) | |||
| Quartile 1, highest deprivation | 1.34 | (1.11, 1.62) | 0.003 |
| Quartile 2 | 1.12 | (0.92, 1.36) | 0.26 |
| Quartile 3 | 1.23 | (1.01, 1.49) | 0.04 |
| Quartile 4, lowest deprivation | Ref | ||
| Unknown | 1.10 | (0.66, 1.85) | 0.71 |
| International participant (compared to US participant with private insurance and lowest deprivation quartile) | 0.98 | (0.79, 1.22) | 0.84 |
| Menopausal Status | |||
| Premenopausal | Ref | ||
| Postmenopausal | 1.08 | (0.87, 1.34) | 0.48 |
| Tumor Size in the largest dimension | |||
| Less than or equal to 2.0 cm | Ref | ||
| Greater than 2.0cm | 1.06 | (0.93, 1.22) | 0.38 |
| Progesterone receptor expression | |||
| Negative | Ref | ||
| Positive | 0.75 | (0.61, 0.91) | 0.004 |
| Unknown | 0.51 | (0.28, 0.92) | 0.03 |
| Oncotype Dx Recurrent Score (RS) | |||
| Less than or equal to 10 | Ref | ||
| 11-25 | 0.80 | (0.67, 0.94) | 0.007 |
| Greater than 25 | 0.83 | (0.63, 1.08) | 0.16 |
| First Endocrine Therapy | |||
| Aromatase Inhibitor (AI) | Ref | ||
| Tamoxifen | 1.00 | (0.84, 1.20) | 0.96 |
| Tamoxifen & AI | 1.27 | (0.70, 2.32) | 0.44 |
| Ovarian Function Suppression | 1.05 | (0.72, 1.54) | 0.81 |
| Other | 3.68 | (1.35,10.06) | 0.01 |